Loading...
Docoh

Option Care Health Inc. - Registered Shares (OPCH)

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, the company works compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through its clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates.

Company profile

Ticker
OPCH
Exchange
CEO
John Rademacher
Employees
Incorporated
Location
Fiscal year end
Former names
BioScrip, Inc., MIM CORP
SEC CIK
Subsidiaries
Applied Health Care, LLC • BioScrip Infusion Services, Inc. • BioScrip Infusion Services, LLC • BioScrip Medical Supply Services, LLC • BioScrip PBM Services, LLC • BioScrip Pharmacy (NY), Inc. • BioScrip Pharmacy Services, Inc. • BioScrip Pharmacy, Inc. • Bradhurst Specialty Pharmacy, Inc. • CHI Holding Corp. ...
IRS number
50489664

OPCH stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

27 Jul 22
9 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 22 Pate R Carter Common Stock Sell Dispose S No Yes 33.37 1,923 64.17K 99,381
8 Jul 22 Pate R Carter Common Stock Sell Dispose S No Yes 30 1,923 57.69K 101,304
6 Jun 22 Harriet Booker Common Stock, par value $0.0001 Sell Dispose S No Yes 30.25 6,000 181.5K 80,760
6 Jun 22 Harriet Booker Common Stock, par value $0.0001 Option exercise Acquire M No No 10.12 5,249 53.12K 86,760
6 Jun 22 Harriet Booker Employee Stock Option Common Stock, par value $0.0001 Option exercise Dispose M No No 10.12 5,249 53.12K 0
20 May 22 Golding David W Common Stock, par value $0.0001 Grant Acquire A No No 0 8,223 0 92,464
20 May 22 Harry M Jansen Kraemer JR Common Stock, par value $0.0001 Grant Acquire A No No 0 9,555 0 159,965
96.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 231 226 +2.2%
Opened positions 28 46 -39.1%
Closed positions 23 28 -17.9%
Increased positions 87 88 -1.1%
Reduced positions 80 62 +29.0%
13F shares Current Prev Q Change
Total value 4.91B 4.85B +1.3%
Total shares 175.18M 174.78M +0.2%
Total puts 0 0
Total calls 129.5K 258.23K -49.9%
Total put/call ratio
Largest owners Shares Value Change
WBA Walgreens Boots Alliance 37.25M $971.03M 0.0%
FMR 18.82M $537.5M +12.1%
BLK Blackrock 16.52M $471.89M -0.4%
Vanguard 13.94M $397.99M -0.3%
TROW T. Rowe Price 9.71M $277.41M -3.4%
Park West Asset Management 5.85M $167.2M +1.4%
STT State Street 4.54M $129.66M +3.0%
Ubs Global Asset Management Americas 4.15M $118.43M +11.2%
BLVGF Bellevue 3.23M $92.33M +10.6%
Marshall Wace 2.87M $82.03M -5.0%
Largest transactions Shares Bought/sold Change
ARES Ares Management 0 -2.08M EXIT
FMR 18.82M +2.03M +12.1%
Norges Bank 0 -1.5M EXIT
Loomis Sayles & Co L P 2.68M +1.06M +65.1%
Putnam Investments 1.17M +936.45K +400.7%
Allspring Global Investments 2.61M -796.57K -23.4%
Manufacturers Life Insurance Company, The 971.26K +738.37K +317.0%
GS Goldman Sachs 2.25M +694.54K +44.8%
Gilder Gagnon Howe & Co 1.29M -536.82K -29.3%
Ghisallo Capital Management 0 -500K EXIT

Financial report summary

?
Risks
  • Our revenue and profitability will decline if the pharmaceutical industry undergoes certain changes, including limiting or discontinuing research, development, production and marketing of the pharmaceuticals that are compatible with the services we provide.
  • If we lose relationships with managed care organizations (“MCOs”) and other non-governmental third party payers, we could lose access to a significant number of patients and our revenue and profitability could decline.
  • The healthcare industry is highly competitive.
  • If we are unable to maintain relationships with existing patient referral sources, our business and consolidated financial condition, results of operations, and cash flows could be materially adversely affected.
  • Changes in industry pricing benchmarks could adversely affect our financial performance.
  • Changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing, could adversely affect our business and financial results.
  • A disruption in pharmaceutical and medical supply could adversely impact our business.
  • A shortage of qualified registered nursing staff, pharmacists and other professionals could adversely affect our ability to attract, train and retrain qualified personnel and could increase operating costs.
  • Introduction of new drugs or accelerated adoption of existing lower margin drugs could cause us to experience lower revenues and profitability when prescribers prescribe these drugs for their patients or they are mandated by Third Party Payers.
  • Failure to develop new services or adapt to changes and trends within the healthcare industry may adversely affect our business.
  • Changes in future business conditions could cause business investments and/or recorded goodwill to become impaired, and our financial condition and results of operations could suffer if there is an impairment of goodwill.
  • A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability.
  • Federal actions and legislation may reduce reimbursement rates from governmental payers and adversely affect our results of operations.
  • Delays in reimbursement may adversely affect our liquidity, cash flows and operating results.
  • We are subject to pricing pressures and other risks involved with Third Party Payers.
  • We face periodic reviews and billing audits by governmental and private payers, and these audits could have adverse findings that may negatively impact our business.
  • If any of our pharmacies fail to comply with the conditions of participation in the Medicare program, that pharmacy could be terminated from Medicare, which could adversely affect our consolidated financial statements.
  • We cannot predict the impact of changing requirements on compounding pharmacies.
  • Our existing indebtedness could adversely affect our business and growth prospects.
  • Despite our indebtedness, we may still incur significantly more debt. This could exacerbate the risks associated with our substantial leverage.
  • We may not be able to generate sufficient cash flow to service all of our indebtedness, and may be forced to take other actions to satisfy our obligations under such indebtedness, which may not be successful.
  • As of December 31, 2021, Walgreens Boots Alliance, Inc. (“Walgreens”) is our largest stockholder and has the ability to exercise significant influence over decisions requiring our stockholders’ approval.
  • Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management, even if beneficial to our stockholders.
  • Our third amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
  • We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock.
  • The COVID-19 pandemic and other potential pandemic events could adversely impact our business operations, results of operations, cash flows and financial position.
  • Pending and future litigation could subject us to significant monetary damages and/or require us to change our business practices.
  • We may be subject to liability claims for damages and other expenses that are not covered by insurance.
  • Pressures relating to downturns in the economy could adversely affect our business and consolidated financial statements.
  • Acquisitions, strategic investments and strategic relationships involve certain risks.
  • Cybersecurity risks could compromise our information and expose us to liability, which may harm our ability to operate effectively and may cause our business and reputation to suffer.
  • Our business is dependent on the services provided by third party information technology vendors.
  • Failure to maintain effective internal control over our financial reporting could have an adverse effect on our ability to report our financial results on a timely and accurate basis.
  • Acts of God such as major weather disturbances could disrupt our business.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: attempted, cautionary, economy, fuel, harbor, hereof, important, incorrect, inflation, inflationary, intend, intended, low, lower, macroeconomic, open, platform, Private, prove, reader, Reform, relying, safe, suggested, understanding
Removed: assessed, cautioned, classified, clear, corrected, correction, error, expressed, implemented, implied, improperly, individual, materiality, NOL, potential, purely, qualitatively, quantitatively, reliance, repayment, September, speak, treated, undue